Suwon-si, South Korea

Sang Koo Park



Average Co-Inventor Count = 7.9

ph-index = 2

Forward Citations = 7(Granted Patents)


Location History:

  • Suwon-si, KR (2006 - 2008)
  • Yongin-si, KR (2010)

Company Filing History:


Years Active: 2006-2010

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Sang Koo Park

Introduction

Sang Koo Park is a prominent inventor based in Suwon-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of 4 patents to his name, his work has the potential to impact various medical treatments.

Latest Patents

One of his latest patents involves a humanized antibody specific for tumor necrosis factor-alpha. This innovation is prepared from a mouse monoclonal antibody using the CDR grafting method. The resulting antibodies exhibit an antigen binding affinity similar to the original mouse monoclonal antibody while demonstrating significantly low immunogenicity. This makes them effective for treating diseases related to hTNF-α, such as rheumatoid arthritis, Crohn's disease, and asthma. Another notable patent is a humanized antibody against the S-surface antigen of the hepatitis B virus. This invention also shows similar antigen-binding affinity to a mouse monoclonal antibody and significantly low immunogenicity, making it useful for treating chronic hepatitis B and preventing HBV infection in patients undergoing liver transplantation.

Career Highlights

Sang Koo Park is currently associated with Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has allowed him to focus on innovative solutions in the field of antibody development. His contributions have been instrumental in advancing therapeutic options for various diseases.

Collaborations

Sang Koo Park has collaborated with notable colleagues such as Tae Hyoung Yoo and Moo Young Song. Their combined expertise has fostered a productive environment for research and development in biotechnology.

Conclusion

Sang Koo Park's innovative work in the field of humanized antibodies showcases his dedication to advancing medical science. His patents reflect a commitment to improving treatment options for patients suffering from serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…